T W Hepburn1, M C Totoritis, C B Davis. 1. Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539 (UW2720), King of Prussia, PA 19406, USA. timothy_w_hepburn@gsk.com
Abstract
OBJECTIVE: Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In initial studies of clenoliximab, we investigated the hypothesis that the decrease in cell surface CD4 is the result of antibody-mediated stripping from the cell surface. METHODS: Patients received single or multiple intravenous infusions of clenoliximab as follows: 0.05, 0.2, 1, 5, 10 or 15 mg/kg (n=3-5/group); 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2 (n=12/group). Blood was collected for up to 16 weeks and pharmacokinetic and pharmacodynamic assessments were conducted using immunoassay and flow cytometry. RESULTS:CD4 count was largely unaffected by clenoliximab treatment. Dose-dependent CD4 coating, down-modulation and stripping were observed. Maximal down-modulation persisted for an increasing period as dose increased, while soluble CD4-clenoliximab complexes accumulated. The amount of CD4 in soluble complex was as much as 20 times the amount of cell-associated CD4. For the same total dose, administration of higher doses, less frequently, resulted in pharmacodynamic profiles similar to those of lower doses administered more frequently. CONCLUSION: Decrease in the density of CD4 on the T-lymphocyte surface is caused by antibody-mediated stripping.
RCT Entities:
OBJECTIVE:Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In initial studies of clenoliximab, we investigated the hypothesis that the decrease in cell surface CD4 is the result of antibody-mediated stripping from the cell surface. METHODS:Patients received single or multiple intravenous infusions of clenoliximab as follows: 0.05, 0.2, 1, 5, 10 or 15 mg/kg (n=3-5/group); 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2 (n=12/group). Blood was collected for up to 16 weeks and pharmacokinetic and pharmacodynamic assessments were conducted using immunoassay and flow cytometry. RESULTS:CD4 count was largely unaffected by clenoliximab treatment. Dose-dependent CD4 coating, down-modulation and stripping were observed. Maximal down-modulation persisted for an increasing period as dose increased, while soluble CD4-clenoliximab complexes accumulated. The amount of CD4 in soluble complex was as much as 20 times the amount of cell-associated CD4. For the same total dose, administration of higher doses, less frequently, resulted in pharmacodynamic profiles similar to those of lower doses administered more frequently. CONCLUSION: Decrease in the density of CD4 on the T-lymphocyte surface is caused by antibody-mediated stripping.
Authors: Bianca Helling; Martin König; Benjamin Dälken; Andre Engling; Wolfgang Krömer; Katharina Heim; Holger Wallmeier; Jürgen Haas; Brigitte Wildemann; Brigitte Fritz; Helmut Jonuleit; Jan Kubach; Theodor Dingermann; Heinfried H Radeke; Frank Osterroth; Christoph Uherek; Niklas Czeloth; Jörg Schüttrumpf Journal: Immunol Cell Biol Date: 2014-12-16 Impact factor: 5.126
Authors: Sophie E Berends; Tamara J van Steeg; Maurice J Ahsman; Sharat Singh; Johannan F Brandse; Geert R A M D'Haens; Ron A A Mathôt Journal: J Pharmacokinet Pharmacodyn Date: 2019-09-05 Impact factor: 2.745
Authors: Elisa Claeys; Eva Pauwels; Stephanie Humblet-Baron; Becky Provinciael; Dominique Schols; Mark Waer; Ben Sprangers; Kurt Vermeire Journal: Front Immunol Date: 2021-04-21 Impact factor: 7.561
Authors: Lisa M McGinley; Kevin S Chen; Shayna N Mason; Diana M Rigan; Jacquelin F Kwentus; John M Hayes; Emily D Glass; Evan L Reynolds; Geoffrey G Murphy; Eva L Feldman Journal: Clin Transl Med Date: 2022-09